Autoinjectors Market – By Type, By Route of Administration, By Therapy, By End Use - Global Forecast, 2025 - 2034

Autoinjectors Market Size

The global autoinjectors market was valued at USD 68.1 billion in 2024 and is projected to exhibit 14.3% CAGR from 2025-2034. Increased incidence of anaphylaxis and diabetes and generic availability of autoinjectors are driving market revenue growth in the market.
 

The increase in incidence of diabetes and anaphylaxis is driving the market for autoinjectors, since these require rapid and reliable administration of medicine. Owing to the increased prevalence of diabetes worldwide, demand for insulin-delivery devices like autoinjectors has heightened since they offer a more effective and patient-friendly method to administer insulin injections. Indeed, the International Diabetes Federation (IDF) approximated that in 2021, there were close to 537 million adults living with diabetes.
 

In addition, the increasing incidence of anaphylactic reactions, which are typically induced by allergens such as foods, insect bites, or medication, has created the need for the widespread use of autoinjectors for the immediate administration of epinephrine. The convenience of use, portability, and accuracy of dosing ability of autoinjectors are the main reasons for their extensive use for the treatment of such conditions. As diabetes and anaphylaxis continue to increase, the autoinjector market is expected to grow during the forecast years.
 

Also, the presence of generic autoinjectors is further driving the revenue increase in the autoinjectors market, as they are an economical substitute for branded products. With the growing need for cost-effective healthcare solutions, generic autoinjectors provide the same performance and reliability as branded products, but at a lower cost. This has significantly increased its popularity among healthcare providers and patients, which has supplemented the demand for autoinjectors, especially in the developing countries where affordability counts.
 

Autoinjectors are drug delivery devices that inject a pre-set dose of drug into the body automatically, usually by way of a needle. They are used to administer drugs for self-injection most frequently for diseases such as allergies, diabetes, rheumatoid arthritis, and other long-term diseases. Autoinjectors are simple to use, typically with a spring mechanism for the administration of the drug with the minimum effort, making them particularly well suited for those patients who require multiple injections.
 

Autoinjectors Market Trends

• Advances in autoinjectors in recent times have been of great impact in expanding the market. Many of the autoinjectors now contain Bluetooth or smart technology, enabling them to connect with mobile applications for tracing injections in real-time. This enables patients and healthcare professionals to track medication compliance so that doses are not skipped, and patient outcomes are enhanced.
   
• Moreover, some autoinjectors are adopting needle-free technology, using high-pressure air to inject the medication through the skin without a needle. This reduces the pain and discomfort of traditional injections, encouraging patient compliance, especially in patients with needle phobia.
   
• Moreover, newer generations of autoinjectors contain less complicated design that facilitates ease of use for patients, including those with disabled dexterity, so that it becomes effortless to self-administer medication. Ergonomic design consists of smoother grip shapes, less harsh materials, and simplified mechanism for operating.
• Such changes are playing an integral part in bringing efficiency, comfort, as well as the overall patient experience, adding towards the growth of the adoption in the market.
   

Trump Administration Tariffs

• Foreign raw materials, such as stainless steel, specialty polymers, and electronic components imported particularly from China, increased production costs of autoinjectors globally. Entities depending on U.S.-based facilities or U.S.-imported components faced significantly increased costs at once.
   
• Trade restrictions led to problems in global supply chains, especially for precise parts like springs, plungers, and drive mechanisms from the Asia Pacific. These disruptions delayed production schedules and complicated logistics for various pharmaceutical and medical device firms.
   
• Tariff uncertainty affected the strategic planning of international businesses, with some delaying or reducing plans to expand in the U.S. autoinjector market, which is a significant source of revenue for chronic and emergency drug delivery devices.
   
• Higher production and shipping costs raised costs to consumers in some regions. This may make it more difficult for individuals in low- and middle-income countries to access autoinjectors for long-term illnesses such as rheumatoid arthritis, multiple sclerosis, and anaphylaxis.
   

Autoinjectors Market Analysis

Based on type, the market is segmented into disposable and reusable. The disposable segment dominates the market with a share of 66.7% in 2024.
 

• Single-use autoinjectors offer a convenient option to patients, particularly those with chronic diseases in which they require regular injections. Since the device is intended for a single use, it minimizes cleaning and maintenance, and hence it is more convenient for patients to use without the requirement of special knowledge or extra effort.
   
• Moreover, single-use autoinjectors are intended for use once, which also decreases the risk of infection or contamination by reused devices. This is particularly important for injecting medications since cleanliness and sanitary conditions are paramount in preventing complications and ensuring patient safety.
   
• Additionally, post COVID-19, there has been a shift towards home-based care among diabetes patients. This, in turn, has made portable and easy-to-use devices, like disposable autoinjectors, increasingly preferred.
   

Based on route of administration, the autoinjectors market is segmented into subcutaneous and intramuscular. The subcutaneous segment dominated the market with a share of 92.1% in 2024.
 

• Subcutaneous injections are comparatively easier for patients to administer than intramuscular injections. Subcutaneous injections tend to be less painful and can be given at home, which means that patients with chronic conditions such as diabetes can self-administer their treatment. This convenience significantly widens the market for subcutaneous autoinjectors.
   
• In addition, numerous biologics, including those for diabetes insulin and monoclonal antibodies against other chronic disorders, are taken subcutaneously. Hence, subcutaneous autoinjectors have a larger market, extending the needs for more patients in various therapeutic applications, driving the segment growth.
   

Based on therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapies. The diabetes segment is anticipated to obtain the highest CAGR growth of 15.8% during forecast period.
 

• The increasing number of cases of diabetes worldwide, mainly type 1 and type 2 diabetes, is fueling the growth for insulin and other injectable products. Since diabetes is a long-term disease that has to be medicated continuously, the usage of autoinjectors proves to be an easier and less painful way of injecting insulin, thus boosting growth in this segment.
   
• Additionally, ongoing development in insulin delivery devices, like prefilled pens and intelligent autoinjectors, is facilitating better management of diabetes by patients. These devices have more accurate dosing, improved tracking capabilities, and easier usability, making them more popular with patients, hence driving the segment's growth at a faster pace.
   
• For instance, NovoPen Echo Plus, a smart insulin pen offered by Novo Nordisk, records dosing information and integrates with digital platforms for better diabetes management. Similarly, Eli Lilly and Company also provide their own Tempo Pen + Tempo Smart Button which is a pen integrated with a bluetooth enabled tempo smart button which can be affixed to the pen, and it relays dose information to the mobile application.
   

Based on end use, the autoinjectors market is segmented into hospital and clinics, homecare settings, and other end users. The homecare settings segment dominated the market with a share of 64% in 2024.
 

• With increasing patients demanding independence in controlling their health conditions, the option of self-administering injections at home has become a major consideration.
   
• Autoinjectors provide an easy, painless method for patients to control chronic diseases such as diabetes, rheumatoid arthritis, and anaphylaxis, without the necessity of frequent hospital visits, hence making homecare settings the most desirable option.
   
• Additionally, with increasing incorporation of telemedicine and remote monitoring of patients, homecare for patients requiring injections on a routine basis is progressively possible. Patients can be injected with autoinjectors at home while healthcare personnel watch from a distance to afford a second line of care as well as patient compliance with therapeutic protocols.
   

In 2024, the U.S. led the North American market, generating a revenue of about USD 29.9 billion.
 

• The U.S. boasts a high volume of patients with chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis. The growing chronic disease burden necessitates the demand for self-administered drugs, which has led autoinjectors to be the favored solution in the treatment of these diseases.
   
• For instance, as per the Centers for Disease Control and Prevention (CDC), about 38.4 million people of all ages in the U.S. were affected with diabetes in 2021. Moreover, about 78.8% of people aged 18 and above, that were affected with diabetes, were reported to have at least one usual source of diabetes care, including doctors or healthcare professionals. This has driven the demand for autoinjectors in the country.
   
• Moreover, the U.S. is a hub for healthcare innovation. Improvements in autoinjector technologies, including easy-to-use designs, needle-free technologies, and in-built safety mechanisms, are driving market growth. The availability of advanced autoinjector devices is driving their increased adoption.
   

The UK is set to see a robust expansion in its autoinjectors market from 2025 to 2034.
 

• The National Health Service (NHS) and other UK healthcare systems encourage the application of inexpensive treatments such as autoinjectors for chronic disease management. The drive by the government to improve homecare alternatives also drives demand for autoinjectors.
   
• In addition, home-based healthcare is gaining momentum in the UK, particularly for the management of chronic diseases. With the use of autoinjectors, patients can easily administer medication to themselves, reducing hospital visits and improving a worthwhile choice for healthcare professionals and patients alike.
   

Japan's autoinjectors market is set for lucrative growth from 2024 to 2034.
 

• Japan boasts one of the fastest-growing elderly populations in the world. Elderly patients have chronic diseases including diabetes and arthritis that need to be treated through continuous medication. Autoinjectors are an easy choice for such patients, which is driving market growth.
   
• In addition, Japan is also famous for its medical technological advancements. More user-friendly, easy-to-use, and sophisticated autoinjector devices have improved the demand, particularly among the elderly, since self-injections are becoming a common practice.
   
• Moreover, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has developed “Sakigake” designation system which accelerates approval processes for combination products (drug + device). This promotes the development and expansion of the connected devices market in Japan including for autoinjectors.
   

Saudi Arabia's autoinjectors market is expected to witness substantial growth during the forecast period.
 

• Saudi Arabia is facing growing instances of chronic diseases, the most prominent of which is diabetes that seeps deep into a high percentage of the population. Autoinjectors are widely applied in the treatment of diabetes as well as other chronic diseases, thus the surge in market expansion.
   
• Moreover, Saudi Arabia's Vision 2030 strategy emphasizes improving the healthcare infrastructure and increasing access to modern healthcare technologies. This includes the promotion of self-injection devices like autoinjectors for greater patient convenience and reduced hospital visits, which is propelling market growth.
   

Autoinjectors Market Share

The autoinjector market is diversified and driven by a broad spectrum of global and regional players offering innovative solutions to address the increasing demand for self-administration of medication and improved patient convenience. Companies such as SHL Medical, Ypsomed, Becton, Dickinson and Company, Amgen, and Eli Lilly and Company contributes to about 60% of the market share. Key players significantly rely on product launches and innovation to sustain their market share and gain competitive edge.
 

Competition in this market is driven by ongoing technological advancement, strict adherence to regulatory standards, and the ability to offer customized solutions that meet the needs of patients, healthcare providers, and homecare settings. In the emerging markets, where affordability is a high-priority factor, incumbent international players are challenged to deliver quality autoinjectors at competitive prices. Local manufacturers take advantage of this need by providing more affordable options, forcing international players to set prices in response while maintaining product reliability, safety, and regulatory compliance.
 

Autoinjectors Market Companies

Some of the eminent market participants operating in the autoinjectors industry include:

• AbbVie
• Amgen
• Antares Pharma
• Becton, Dickinson and Company
• Eli Lilly and Company
• GlaxoSmithKline
• Halozyme
• Johnson & Johnson
• Mylan
• Novo Nordisk
• Owen Mumford
• SHL Medical
• Teva pharmaceuticals
• West Pharmaceutical Services
• Ypsomed
   
• Amgen stands well-positioned in the market for autoinjectors with its portfolio of patient-centric, biosimilar and biologic medicines being delivered via one-touch, easy-to-use SureClick autoinjector systems meant for home use. With its integration of highly advanced delivery technologies with therapies used to treat long-term conditions like rheumatoid arthritis and osteoporosis, Amgen stands well-positioned in effective solutions for drug delivery.
   
• Eli Lilly is a leading company in the autoinjector market with its range of diabetes and autoimmune therapy products such as Emgality and Trulicity pens. The patient-developed injectors are easy to administer. The union of clinical performance and easy-to-use administration has turned Eli Lilly's autoinjectors into a doctor- and patient-preferred product.
   
• Ypsomed is a specialist in injection systems with emphasis on developing and tailoring autoinjector platforms for pharmaceutical companies. YpsoMate autoinjector platform, being modulated and adaptable in regulatory compliance, has gained widespread industry approval. Ypsomed provides turnkey device development, manufacturing, and support solutions so that pharmaceutical companies can avail autoinjector solutions for biologics, particularly high-viscosity formulations. Ypsomed incorporates digital health features for optimizing therapy management and patient engagement.
   

Autoinjectors Industry News:

• In October 2024, BD, a leading global medical technology company, announced a strategic collaboration with Ypsomed, a leading developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs. This strategic partnership enabled BD to strengthen its capabilities in delivering advanced self-injection solutions, expand its product portfolio for biologic drug delivery, and enhance its competitiveness in the growing autoinjectors market.
   
• In November 2024, Amneal Pharmaceuticals announced the resubmission to the U.S. Food and Drug Administration (FDA) of its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector. The FDA previously issued a complete response letter due to facility inspection issues, prompting Amneal to transfer production in-house.
   
• In May 2023, Coherus BioSciences announced the U.S. launch of the UDENYCA Autoinjector. This product is a single-dose, prefilled autoinjector for pegfilgrastim (pegfilgrastim-cbqv) that can be administered in both in-office and at-home settings. The UDENYCA Autoinjector is designed to offer patients greater choice, independence, and flexibility in their treatment following chemotherapy.
   
• In October 2022, Ypsomed announced the launch of YpsoMate 5.5 autoinjector which is compatible with liquid medications ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 Is the last addition to the ever growing Ysomate family of devices and is built on the well-known technology of YpsoMate 2.25 Pro.
   

The autoinjectors market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type  

• Disposable
• Reusable

Market, By Route of Administration

• Subcutaneous
• Intramuscular

Market, By Therapy

• Rheumatoid arthritis
• Multiple sclerosis
• Anaphylaxis
• Diabetes
• Other therapies

Market, By End Use

• Hospital and clinics
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE